Targeting Liver Metastases in Uveal Melanoma: ATX-LPA Mediated Immunosuppression and Novel Therapeutic Approaches - Scorecard - MDSpire

Targeting Liver Metastases in Uveal Melanoma: ATX-LPA Mediated Immunosuppression and Novel Therapeutic Approaches

  • By

  • A. Turner, Jacqueline

  • D'Antonio, Marc

  • Montane, Heather

  • MacBeth, Morgan

  • Katsnelson, Elizabeth

  • Robinson, William

  • Tobin, Richard

  • Couts, Kasey L.

  • Markovic, Svetomir N

  • Torres, Raul M

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Addressing Liver Metastasis in Uveal Melanoma: The Role of ATX-LPA in Immune Suppression and Innovative Treatment Strategies

At a Glance

CategoryDetail
Condition
Key MechanismsATX-LPA axis mediates immune suppression and affects CD8+ T cell function.
Target Population
Care Setting

Key Highlights

  • Uveal melanoma shows a strong tendency for liver metastasis.
  • Impaired CD8+ T cell function is linked to liver-mediated immune suppression.
  • The ATX-LPA axis is identified as a key immunoregulatory pathway.

Guideline-Based Recommendations

Diagnosis

  • Evaluate liver involvement in patients with uveal melanoma.

Management

    Monitoring & Follow-up

    • Assess CD8+ T cell function and immunosuppressive markers in hepatic metastasis.

    Risks

      Patient & Prescribing Data

      Targeting the ATX-LPA axis may improve immune responses.

      Clinical Best Practices

        Related Resources & Content

          Original Source(s)

          Targeting Liver Metastases in Uveal Melanoma: ATX-LPA Mediated Immunosuppression and Novel Therapeutic Approaches

          • by A. Turner, Jacqueline , D'Antonio, Marc , Montane, Heather , MacBeth, Morgan , Katsnelson, Elizabeth , Robinson, William , Tobin, Richard , Couts, Kasey L., Markovic, Svetomir N, Torres, Raul M

          • May 29, 2026

          Related Content

          A model combining deep learning and ensemble learning for melanoma recognition via dermoscopy

          Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

          Editorial: Immune-related biomarkers in skin and breast cancer: innovations in immunological diagnostics and therapies